Search

M2 PRESSWIRE-June 5, 2024-: Alopecia Areata Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Crp., Novartis [...]

M2 PRESSWIRE-November 21, 2023-: Pulmonary Arterial Hypertension Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Novartis, GSK, Johnson &Johnson, Arena Pharma, Bayer [...]

M2 PRESSWIRE-June 7, 2023-: Alopecia Areata Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Inc., Novartis [...]

M2 PRESSWIRE-May 2, 2023-: Chronic Lymphocytic Leukemia Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook (C)1994-2023 [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis will present new data from its oncology portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis and Molecular Partners today announced that Part A of the EMPATHY clinical trial1 that compared single intravenous doses [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for branaplam (LMI070) [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis today announced the first interpretable results from year two (week 100) of the Phase III KESTREL study. KESTREL [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis, a leader in rheumatology and immuno-dermatology, today announced new analyses from the two-year positive Phase III JUNIPERA study, [...]

Basel, Switzerland: Novartis International AG has issued the following press release: As the threat of resistance to current malaria treatment grows, Novartis and MMV have reported positive results of a [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis today announced positive results from two Phase III clinical trials assessing Beovu(r) (brolucizumab) 6 mg versus aflibercept 2 [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis today announced that the U.S. Food and Drug Administration (FDA) has determined that OAV-101 intrathecal (IT) clinical trials [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis today announced that The New England Journal of Medicine (NEJM) published positive results from the Phase III REACH3 [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis announced today results from the pivotal Phase III RATIONALE 302 trial showing the investigational anti-PD-1 immune checkpoint inhibitor [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah(r) (tisagenlecleucel) [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Detailed results from the pivotal Phase III REACH3 study demonstrate Jakavi(r) (ruxolitinib) significantly improved outcomes across a range of [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis announced today that HER-MES, the first Phase IV, randomized, double-blind, double-dummy, head-to-head study of Aimovig(r) (erenumab) against topiramate, [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis, a leader in immuno-dermatology and rheumatology, today announced data from two pivotal international Phase III studies, which show [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis today announced that results of two new post-hoc analyses of the Phase III HAWK and HARRIER clinical trials [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis today reported the first interpretable results of the Phase III KITE study, assessing the efficacy and safety of [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis, a leader in rheumatology and immuno-dermatology, today announced results from the EXCEED head-to-head trial comparing Cosentyx(r) (secukinumab) to [...]

Basel: Novartis International AG has issued the following press release: Novartis, a leader in rheumatology and immuno-dermatology, today announced results from the EXCEED head-to-head trial comparing Cosentyx(r) (secukinumab) to Humira(r)* [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis today announced that investigational, once-daily, inhaled QVM149 (indacaterol acetate, glycopyrronium bromide and mometasone furoate or IND/GLY/MF) was superior [...]

Basel, Switzerland: Novartis International AG has issued the following press release: Novartis today announced that investigational, once-daily, fixed-dose inhaled QMF149 (indacaterol acetate and mometasone furoate or IND/MF) was superior to [...]

SWITZERLAND: Novartis International AG has issued the following press release: Novartis today announced positive topline data from two phase III, multicenter studies evaluating omalizumab (Xolair(r)) for the treatment of adults [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment . Processed and [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC [...]

SWITZERLAND: Novartis International AG has issued the following press release: Novartis today announced 14-month results from the pivotal JULIET clinical trial showing ongoing durable responses are achievable with Kymriah(r) (tisagenlecleucel) [...]

Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable (1) Patients had a 65% chance [...]

- Kisqali plus fulvestrant demonstrated superior efficacy, with a median PFS of 20.5 months vs. 12.8 months for fulvestrant alone, among overall study population of first- and second-line postmenopausal patients [...]

SWITZERLAND: Novartis International AG has issued the following press release: Novartis announced new positive brolucizumab (RTH258) data in neovascular age-related macular degeneration (nAMD) from a pre-specified secondary analysis of the [...]

- Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / New Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval . Processed and transmitted by Nasdaq Corporate Solutions. [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Novartis to present predictability data for brolucizumab in nAMD from pivotal HAWK and HARRIER trials at ARVO . Processed and transmitted [...]

Basel: Novartis International AG has issued the following press release: Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS . Processed and [...]

-- EXPAND shows oral siponimod (BAF312) is the first investigational disease-modifying therapy in a large trial that meaningfully delayed disability progression in typical secondary progressive MS (SPMS) patients(1) -- Results [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine . Processed and transmitted by Nasdaq Corporate Solutions. [...]

- Kisqali plus an oral endocrine partner demonstrated significant efficacy with sustained benefit of nearly two years (median PFS 23.8 vs 13.0 months for endocrine therapy alone) and an early [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Novartis Kisqali(R) is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment [...]

- Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Novartis canakinumab (ACZ885) reduced cardiovascular risk by 25% in subgroup of CANTOS Phase III trial participants . Processed and transmitted by [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Novartis reports positive results from Phase III trial of Kisqali(R) (ribociclib) combination therapy in premenopausal women with HR+/HER2- advanced or metastatic [...]

- Cosentyx (secukinumab) is the first and only fully human IL-17A antagonist to show sustained skin clearance rates at 5 years in Phase III in psoriasis(1) - Landmark data show [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Sandoz proposed biosimilar rituximab accepted for review by the FDA . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS . Processed and transmitted by [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / NEJM publishes full analysis of Rydapt(R) (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) . Processed [...]

London: NOVARTIS AG CHF0.50(REGD) has issued the following news release: Novartis today announced initial topline results from two pivotal Phase III clinical studies evaluating the safety and efficacy of pegpleranib [...]

(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Novartis provides update on pegpleranib Phase III clinical trial program in patients with neovascular age-related macular degeneration (nAMD or wet AMD) [...]